Microbiome and cancer immunotherapy: a bibliometric analysis.

Why do some patients respond to life-saving cancer immunotherapy while others do not? While immune checkpoint inhibitors (ICIs)—drugs that unmask cancer cells so the immune system can attack them—have revolutionized oncology, they only achieve long-term benefits in roughly 20% to 40% of patients. This massive gap in efficacy suggests a hidden variable is at play.

Researchers are increasingly looking at the human microbiome—the vast community of bacteria, fungi, and viruses living in and on our bodies—as the missing piece of the puzzle. Emerging evidence suggests that the gut microbiome modulates host antitumor immune responses. It effectively acts as a volume knob for immunotherapy. Because this field involves a messy intersection of microbiology, immunology, oncology, and ecology, the research has become difficult to navigate.

A new bibliometric analysis published in the Tan Journal of the Egyptian National Cancer Institute attempts to organize this chaos. By analyzing 3,058 publications from 2010 to early 2026, the study maps how the scientific community has moved from simply asking "what bacteria are there?" to "how can we engineer them to cure cancer?"

Mapping a fragmented frontier

The study identifies a significant challenge in the current state of microbiome research: fragmentation. Because the topic spans multiple disciplines, the knowledge is often siloed. An ecologist might understand community assembly (how species populate an environment). Meanwhile, an oncologist focuses on PD-1 (a protein that acts as an "off switch" for T-cells). Without a unified framework, these insights rarely meet.

Previous attempts to survey this field have fallen short. The authors note that earlier studies often lacked temporal depth. They failed to capture the explosive growth seen between 2021 and 2025. Many also relied on single-tool analyses that missed the bigger picture. Furthermore, existing literature has largely ignored "academic lineages." These are the intellectual inheritances that track how one discovery evolves into a new school of thought.

Triangulating the knowledge landscape

To solve this, the researchers employed a multi-tool approach to triangulate the research landscape. They did not just count papers. They mapped the architecture of ideas. The methodology involved three distinct software layers. They used CiteSpace for detecting "bursts" (sudden surges in keyword popularity). They used VOSviewer for visualizing collaboration networks. Finally, they used the R bibliometrix package to trace knowledge flow.

The authors identify three distinct academic lineages that have shaped the field: 1. Fundamental Immunological Mechanisms: Focused on how the gut microbiome reshapes the tumor microenvironment (the local environment surrounding a tumor). 2. Clinical Translation: Focused on finding biomarkers (biological signs used to predict disease) and using fecal microbiota transplantation (FMT)—the transfer of stool from a donor to a patient—to improve outcomes. 3. Cancer-Specific Research: Focused on the unique microbial signatures of specific tumors, such as colorectal or lung cancer.

By tracking these lineages, the paper reveals how different disciplines feed into one another. As shown in, the field operates through three primary knowledge flow pathways.

Mathematical modeling feeds into molecular genetics. Clinical observations drive molecular biology. Ecological theories are also imported into molecular biology to help us understand microbial communities as complex ecosystems.

From mechanism to precision intervention

The results show a field in the midst of a massive expansion. The authors report an average annual growth rate of approximately 23.0% between 2020 and 2025. There was a notable 46.1% surge in publications in 2025 compared to 2024 .

This indicates a period of extremely rapid scientific acceleration. Geographically, the research is dominated by a "core-periphery" structure .

China and the United States contribute roughly 60.1% of the global output.

Perhaps most importantly, the study tracks the evolution of research priorities through three distinct phases : * Phase I (2013–2018): Exploration of fundamental immunological mechanisms (e.g., dendritic cells and PD-1). * Phase II (2017–2021): A shift toward clinical translation and real-world therapeutic contexts. * Phase III (2019–2025): A move toward "Precision Applications," characterized by keywords like "engineered bacteria" and "precision efficacy prediction."

This transition signifies a move away from broad, descriptive studies toward targeted interventions. Researchers are now attempting to build synthetic biology tools. For example, they are studying attenuated Salmonella Typhimurium (weakened bacteria) to deliver drugs directly to tumors.

Identifying the blind spots

Despite the rapid progress, the authors highlight several critical gaps. First, the research is heavily biased toward the gut bacteriome (bacteria). The roles of the mycobiome (fungi) and the virome (viruses) remain significantly understudied. These organisms likely play important roles in immune modulation.

Second, there is a profound geographic imbalance. While China and the U.S. lead the charge, regions like Africa, South America, and South Asia contribute less than 3% of the research. This is a major problem. Microbiome composition varies wildly across different human populations and diets. A "precision" treatment developed in one part of the world may not work in another.

Finally, the authors warn of a "correlation vs. causation" trap. Much of the current literature is observational. To truly move the needle, the field requires more randomized intervention trials. We need to test whether changing a patient's microbiome actually changes their cancer outcome.

The verdict: A shift toward engineering

Is the field ready for the clinic? The answer is: not quite, but the blueprint is being drawn.

We are currently transitioning from the "discovery" era to the "engineering" era. The research is moving away from simple observations. It is moving toward the development of standardized, predictable microbial therapies. However, progress depends on addressing the lack of standardized analysis pipelines. We also need more randomized clinical trials. For practitioners, the takeaway is clear: watch the shift toward engineered microbes and oral microbiota. These represent the next frontier of personalized oncology.

Figures from the paper